RXRX

Recursion Pharmaceuticals, Inc.

October 15, 2026 · market open

Rarity

1.91

Peak move

+17.91%

Float cap

$1.7B

Recursion Pharmaceuticals is a clinical-stage TechBio company that uses its Recursion Operating System, an integrated AI-native drug discovery and development platform, to discover and develop differentiated medicines. It advances a pipeline of internal programs and strategic partnerships with biopharmaceutical companies, translating biological insights into therapies for patients. Its platform spans biological data generation, small molecule design, and clinical development.

• Key eventmajor_contractOct 15 · 08:45 ET

  Sanofi optioned a potential first-in-class dual targeting inhibitor oral small molecule from its collaboration with Recursion, the first development candidate from the multi-program collaboration, triggering a $10 million milestone payment and bringing total payments to $144 million, with over $300 million in additional milestones possible and a Phase 1 clinical study planned to begin in 2027.

  wireglobenewswire.comWebsec.govWebglobenewswire.comWebglobenewswire.comWebglobenewswire.comWebrttnews.com
• Key eventequity_offeringOct 15 · 08:22 ET

  Recursion priced a $200 million oversubscribed underwritten follow-on offering of 61,540,000 Class A common shares at $3.25 per share, with Leerink, Goldman Sachs, Morgan Stanley and Evercore as joint bookrunners and institutional investors including Janus Henderson, Invus, Longaeva Partners, ARK Invest and Driehaus, expecting about $200 million in gross proceeds and closing on or about October 16, 2026.

  wireglobenewswire.comwireglobenewswire.comWebmarketscreener.comWebglobenewswire.com
• Key eventclinical_readoutOct 15

  Recursion reported updated topline Phase 1b/2 TUPELO data for REC-4881 in familial adenomatous polyposis, showing 87% of patients with reduced total polyp burden and a 47% median decrease at week 13, with a registrational trial targeted for 2027.

  Webseekingalpha.comWebmarketscreener.comWebglobenewswire.comWebglobenewswire.com
• guidance_changeOct 15

  Recursion said its cash, including net proceeds from the concurrently announced $200 million offering, is expected to meet operational needs into 2029, extending its previously disclosed runway.

  Webglobenewswire.com
• equity_offeringOct 14

  Recursion disclosed approximately $86 million in net proceeds from the sale of 23,696,330 Class A shares under its at-the-market program with TD Securities during the quarter ended September 30, 2026.

  Webarchive.fast-edgar.com
• insider_saleOct 13 · 10:29 ET

  Recursion director Robert Hershberg sold 25,000 shares at an average price of $5.00 for about $125,000, and director Blake Borgeson sold 50,000 shares at $4.84 for about $242,000, both under a Rule 10b5-1 plan on October 6, 2026.

  Webmarketbeat.com